Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Clear station article:
http://clearstation.etrade.com/cgi-bin/bbs?post_id=8534397&Refer=
Ann
TON of info on Nanobac:
http://www.wallstreetresources.net/pdf/fc/NNBP.pdf
Ann
Here is a LOT of information on Nanobac:
http://www.nanobac.com/content/management.htm
Ann
Trying to do some DD, that's available and provided - hmm:
http://www.thomsoninvestortools.com/component/firm/aol/view.asp?uid=stocks/financials&view=balanceSheet&country=US&tier=default&symbol=NNBP
Ann
Info on NNBP:
Nanobac Pharmaceuticals wants to pick on something much smaller than its own size. The company is researching nanobacteria, tiny organisms that are 100 times smaller than bacteria, yet apparently cause the body to develop calcium buildup in inconvenient places such as artery walls and kidneys. Such nanobacteria are also called calcifying nano-particles (CNPs) due to their mineralizing properties. Nanobac is researching combinations of already-approved drugs to halt the calcification process. The company also develops and manufactures diagnostic test kits to identify CNPs in the blood. CEO John Stanton controls more than 40% of the company.
Sample Overview
Key Numbers
Company Type Public (OTC: NNBP)
Fiscal Year-End December
2006 Sales (mil.) $0.2
1-Year Sales Growth (65.2%)
2006 Net Income (mil.) ($5.0)
More Financials
Key People
Chairman, CEO, and CFO John Stanton
Co-chairman, Chief Medical Officer, and Head of Operations Benedict Maniscalco
Ann
Sam:
Rate at the time of accusation.
* shareholders will still kip they existing dnag shares
Sam - watcha drinkin? lol
Take care,
Ann
You may be right, but, hard to imagine.
Ann
Altar:
Didn't mean to sound serious. Are you watching the game?
Take care,
Ann
Altar:
"Hardly any activity. Don't you find that a bit strange??"
A bit, but, our IVillage has hardly any activity also. Why not ask a poster here where their favorite hangout is?
Ann
Altar:
There may be another Nanobac board they me be more active on.
Ever think of that?
Ann
Nanobac company presentation:
http://www.nanobac.com/new%20material/Nanobac%202007.pdf
Ann
l0/25/07 - News on NNBP:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23993701
Ann
cha-ching:
Good post.
Ann
Stockholder:
"I don't know about cutting edge"
Read this at your leasure "for starts":
http://pubs.acs.org/cen/nanotechnology/7842/7842nanotechnology.html
There are many articles out there, web sites and successful stocks based on nano technology that are doing superbly. It has also been said that it would someday revolutionize the internet.
Take care,
Ann
"The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University."
Ann
Nanobac's website:
http://www.nanobac.com/
Ann
Stockhldr:
I wonder if you realize how "cutting edge" nano technology is.
Ann
Big Lab:
"We need to get some proper marketing going. The website is an eye sore! If I was a retail customer visiting the site, short..short...visit it would be, etc., etc."
May I suggest that you forward your opinion to DNAP - I had done that over two years ago, or when they had the original unimpressive sight and suggested that they should consider redesigning it. Creativity is not something they focus on. The only page with some merit since the revision is the Ancestry page, from the standpoint of the colors used,IMO. My encouragement and critique of the original site seemed to work from the standpoint that they proceeded to give it a new look and design. However, good web designers are costly and perhaps they didn't want to invest into any more expense at the time. I think a lot of us realize that "presentation" means a lot and is extremely important in selling a company and their products and may well be worth that investment.
Unless you also bring this to their attention, Big, as an investor, they are probably too busy with other endeavors to focus in on our opinions regarding such issues we feel may be important. I happen to totally agree with you.
Good luck to you and I hope you can follow through, as I had.
Take care,
Ann
Ann
Sam:
How does this implicate DNAP in this headline?
Ann
Let's see if this works direct:
http://cosmos.bcst.yahoo.com/up/player/popup/?rn=3906861&cl=6131131&ch=4226713&src=news
Ann
Beckman Coulter's GenomeLab:
http://www.beckmancoulter.com/products/specifications/geneticanalysis/ceq/default.asp
Ann
7/12/2005
SARASOTA, Fla., July 12 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. today announced an upgrade in the throughput and cost efficiency of its automated Beckman Coulter GenomeLab SNPstream genotyping platform.
Ann
Sam:
"20th Anniversary Crimes Against Children Conference
August 11-14, 2008"
Looks as if DNAP is still planning to be around on the above-scheduled conference date.
Take care,
Ann
Sam:
"PRODUCT DISTRIBUTION"
More to this video than just a the mention of product distribution. Gratitude and thank yous given to the long-standing shareholders & that the co. is well into the planning of a stock option.
That's what mainly got my attention. IMO
Take care,
Ann
From DNAP's website:
STATINOME
STATINOME is a genetic test that measures a patient’s likelihood to develop myalgia as an adverse response to the commonly prescribed Statins Lipitor¹ and Zocor². Myalgia is a Statin side-effect condition characterized by muscle pain, and is a first symptom of the potentially fatal muscle-wasting disease rhabdomyolysis. Though only 1 in every 10,000 patients experiences rhabdomyolysis, about 1% of Lipitor¹ and Zocor² users experience its precursor myalgia. Bayers Statin Baycol³ was recently withdrawn from the market due to an unacceptable fatality rate due to rhabdomyolysis.
1-Lipitor is a registered trademark of Pfizer.
2-Zocor is a registered trademark of Merck.
3-Baycol is a registered trademark of Bayer Corporation.
Ann
DNAP's Subsidiaries & Affiliates:
http://dnaprint.com/welcome/subsidiaries/
Ann
Congratulations, Johnnyfiber, on being our new moderator. I see your name is up in lights! - lol
Take care,
Ann
You Tube - Quality Stocks -
Thank you, Johnny...would it directly impact DNAP?
Take care,
Ann
Johnnyfiber:
Can't access your link w/o password, user name or a subscription.
Take care,
Ann
Sam:
Whatever works! Would sure be nice to see it in the works!
Take care,
Ann
Altar:
DNAP is involved with many back-of-the-scene projects and so is Scotland Yard.
Just keep clickin' those beads! - lol Good luck to all of us!
Ann
Altar - "Server in the Sky" story:
http://www.guardian.co.uk/humanrights/story/0,,2241005,00.html
Ann
Today's AOL News article - Merck/cholesterol drug failure:
http://news.aol.com/health/story/_a/cholesterol-drug-not-effective-in-study/20080115091109990001?ncid=NWS00010000000001
Ann
DNAPrint's Life Sciences applications:
http://www.dlsci.com/projects.html
Ann
Semaphore's client list:
http://www.sema4usa.com/clients.htm
Ann
Semaphore:
http://www.sema4usa.com/default.htm
Ann
Wonder why this is still on DNAP website?
Subsidiaries and affiliates
http://www.biofrontera.com
Biofrontera AG is establishing a specialty pharmaceutical business for research and development in dermatology and inflammation. The company’s state-of-the-art laboratory facilities in Leverkusen, Germany, are modern and fully-equipped with sufficient space for projected growth and market expansion.
Biofrontera’s specific expertise lies in the characterization of the pharmacological properties of drug candidates in vitro and in vivo. Biofrontera’s goal is to build a specialty pharmaceutical company with wholly owned products, initially for dermatologic applications. In the future, other pharmaceuticals for larger markets will result from Biofrontera’s in-house research.
In addition, Biofrontera AG holds a wholly-owned subsidiary, Biofrontera Pharmaceuticals GmbH. Biofrontera Pharmaceuticals GmbH has three drugs in pre-clinical and clinical development. Two drugs are in phase II trials; the leading compound is expected to enter the market in 2007/08. Click here to get the latest Biofrontera Bond update.
Ann
Cloud:
"It could be that he's been there all along."
Yes, he was talked about on this board at least two years ago or longer. So, it seems he's been at DNAP a while.
Ann